Magic™ Humanized PD-L1/TIGIT Dual Immune Checkpoint Knock-In Mice

  • Check with publisher
  • Published date: February 11, 2020
    • Shirley, New York, United States

Immune checkpoint-targeted therapy is producing unprecedented clinical results in various kind of cancer patients. Currently, researchers continue to identify an increasing number of immune checkpoints as novel targets for anti-tumor therapy. Co-engagement of multiple immune inhibitory receptors, known as combination immunotherapy, could potentially show better therapeutic outcomes compared with treatment of a single blockade. As always following the research highlight, Creative Biolabs currently offers the Magic™ dual immune checkpoint “humanized” mouse models that are specially designed for in vivo assay, including the humanized PD-L1/TIGIT dual immune checkpoint knock-in mice. https://www.creative-biolabs.com/drug-discovery/therapeutics/magic-humanized-pd-l1-tigit-dual-immune-checkpoint-knock-in-mice.htm

Jerry Carter
0 votes

Useful information

  • Avoid scams by acting locally or paying with PayPal
  • Never pay with Western Union, Moneygram or other anonymous payment services
  • Don't buy or sell outside of your country. Don't accept cashier cheques from outside your country
  • This site is never involved in any transaction, and does not handle payments, shipping, guarantee transactions, provide escrow services, or offer "buyer protection" or "seller certification"

Related listings

  • Magic™ Humanized PD-L1/OX40 Dual Immune Checkpoint Knock-In Mice

    Magic™ Humanized PD-L1/OX40 Dual Immune Checkpoint Knock-In Mice

    Biomedical Sciences Shirley (New York) February 11, 2020 Check with publisher

    Therapeutic antibodies designed to block immune checkpoint receptors or activate immune-stimulatory receptors are a potent strategy to treat cancer and function by modulating a patient's own immune system. The combination immunotherapies that associa...

  • Magic™ Humanized PD-L1/LAG-3 Dual Immune Checkpoint Knock-In Mice

    Magic™ Humanized PD-L1/LAG-3 Dual Immune Checkpoint Knock-In Mice

    Biomedical Sciences Shirley (New York) February 11, 2020 Check with publisher

    Immune checkpoint inhibitors that target coinhibitory T cell molecules are becoming a new pillar of cancer therapy by promoting anticancer immune responses. Nevertheless, current immune checkpoint-based therapies are effective only for a portion of c...

  • Magic™ Humanized CTLA-4/OX40 Dual Immune Checkpoint Knock-In Mice

    Magic™ Humanized CTLA-4/OX40 Dual Immune Checkpoint Knock-In Mice

    Biomedical Sciences Shirley (New York) February 11, 2020 Check with publisher

    Immunotherapy with single immune checkpoint blockade has shown remarkable rapid and durable clinical benefit for various cancer patients, providing a new method of immuno-oncology for cancer treatment. Nowadays, combining immunotherapeutic antibodies...